This study is being offered to patients who have castrate-resistant (also known as hormone-refractory) prostate cancer. The cancer has metastasized or spread outside the prostate area to other parts of the body. The purpose of this study is to evaluate the effects of sequencing hormonal therapies (abiraterone acetate and enzalutamide) and to assess treatment efficacy of these two agents.
Name: Abiraterone acetateDescription: Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.Type: Drug
A - Abiraterone Acetate
Name: EnzalutamideDescription: 160mg PO OD as per standard of care.Type: Drug
B - Enzalutamide
Description: Among mCRPC patients receiving abiraterone acetate and enzalutamideMeasure: Potential biomarkers that are associated with treatment efficacy and/ or resistance Time: 1 year
There is one SNP
In pre-clinical studies, other potential mechanisms of resistance to these agents include increased expression of AR splice variants (abiraterone and enzalutamide) increased expression of CYP17 (abiraterone), upregulation of the stress-activated chaperone protein clusterin (enzalutamide only) and a point mutation (F876L) in the ligand-binding domain of the AR (enzalutamide only). --- F876L ---